(02) 9926 4726

News and Event

New study uses light-activated proteins to fight cancer

An exciting study outlining the development of a new tool for photodynamic therapy (PDT), a selective and minimally invasive cancer treatment, has been published by SV Research Scholar Awardee Dr Dennis Diaz and SV member Dr Andrew Care.

Titled “Bioengineering a Light-Responsive Encapsulin Nanoreactor: A Potential Tool for In Vitro Photodynamic Therapy,” the study was recently published in ACS Applied Materials & Interfaces, a leading journal in the field of nanoscience, and gives a glimpse into how naturally-occurring proteins can be re-programmed to treat cancer.

In a world first, the Care Research Group demonstrated the use of modified protein nanocompartments, called encapsulins, for the successful delivery of a light-activated therapeutic protein that induces tumour cell death.

“By creatively combining the fields of synthetic biology and nanomedicine, we are able to take proteins away from their ‘everyday jobs’ and reprogram them for non-natural applications, like cancer therapy,” Group Leader Dr Care says. “Here, we’ve taken tiny protein nanocompartments that naturally serve as organelles inside bacteria and developed them into biologically-derived tools for PDT.”

To kill tumour cells, first-author Dr Diaz explains, PDT relies on photosensitising agents. When these are triggered by light, they start converting the normal oxygen inside cells into a toxic form of oxygen called ROS (reactive oxygen species). “In this study, we engineered protein nanocompartments to encapsulate photosensitising proteins and deliver them into tumour cells. When we then hit the nanocompartments with light, their protein cargo transformed normal oxygen within the cells into toxic ROS, which killed the tumour cells,” she says.

According to the team, “this technology has significant potential in the personalised treatment of cancers, not only as tool for PDT, but also as a customisable delivery platform for a wide range of therapeutic cargos.”

Dr Diaz and Dr Care talked about the potential of protein-based nanoparticles on Vitalcast two years ago, when they were at the outset of the research journey that led to this publication – listen to the episode here.

Image: A light-activatable ROS-generating encapsulin nanocompartment for in vitro photodynamic therapy (PDT). (a) Diagram showing the cellular delivery, activation and phototoxic effect of encapsulin nanocompartments (Enc) loaded with mini-Singlet Oxygen Generator (Enc-mSOG). Photosensitizing Enc-mSOG enters tumor cells via endocytosis. Upon photoexcitation with blue light, internalized Enc-mSOG converts intracellular O2 into cytotoxic reactive oxygen species (ROS) that induces tumor cell death. (b) Confocal microscopy showing the internalization of fluorescent-labelled Enc (green) by A549 lung cancer cells. (c) Live-cell microscopy of a ROS-sensor (pink) in live A549 cells pre-incubated with Enc or Enc-mSOG and then non-irradiated (Dark) or irradiated with a blue laser (Light). (d) Intracellular ROS levels inside live A549 cells after each treatment; measurements given as normalized integrated density (NI). (e) Cytotoxicity: A549 viability after incubation without (control) or with Enc or Enc-mSOG for different time periods in the dark. Cell viability subsequently determined by MTT assay. (f) Phototoxicity (i.e. in vitro PDT): A549 viability after incubation without (control) or with Enc or Enc-mSOG for different durations in the dark, followed by activation with blue laser light. Cell viability later quantified via MTT assay. Scale bars = 25 µm. Adapted from Diaz et al. ACS Appl Mater Inter 2021 13 (7), 7977-7986.

Read more

New paper investigating a novel approach to SPECT imaging published

Sydney Vital Research Scholar Awardee Harry Marquis was the primary author of a recently published paper investigating a novel approach to SPECT image reconstruction.

Read more

SV researchers lead study demonstrating potential of positrons in cancer therapy

A team of researchers led by Sydney Vital’s director Professor Dale Bailey has published a paper in Scientific Reports demonstrating the potential of positrons in cancer therapy, becoming the first group to do so.

Read more

Sydney Vital Member Plays Critical Role In New Melanoma Test

New test to help predict the progression of melanoma
Sydney Vital member has played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at a high risk of their disease recurring and progressing.
Read more

Sydney Vital Travel Awards 2019 – Round 6

Sydney Vital invites applications for Travel Awards to the value of $1,500 for domestic travel and $3,000 for international travel.

Our aim is to encourage outstanding PhD students, ECRs, researchers and clinicians from within the Sydney Vital network and institutions to present their scientific research progress at national or international conferences.

Read more


Sydney Vital Research Scholar Awards Round 10

Sydney Vital is pleased to invite our members to apply for our Research Scholarship Awards, Round 10.

Read more

Dr Yaser Gholami Awarded a Research Fellowship under Sydney Vital Flagship 3 Program

Sydney Vital is pleased to announce that Dr Yaser Gholami has been awarded a research fellowship under our Flagship 3 program: Nanotechnology and Dr Gholami will be working with and mentored by the current Flagship 3 leader, Prof Alexander Engel.

Read more

Research Fellowship Opportunity – Flagship Program 3: Nanotechnology

Sydney Vital Flagship Program 3 is currently looking to hire a Research Fellow.

Read more

Sydney Vital Contributes In World-First Cancer Trial

A world-first trial of a next-generation cancer treatment which uses a tailored does of radioactive copper to target tumours is underway at Royal North Shore Hospital (RNSH). This new treatment approach had been developed in conjunction with Sydney Vital and Clarity Pharmaceuticals.

Read more

Prof Paul Keall Awarded Translational Program Grant from Cancer Institute NSW

Sydney Vital member Prof Paul Keall is awarded a 2019 Translational Program Grant from the Cancer Institute NSW.

Read more